TrialJAMA2023

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.

Jianming Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.